Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo | Latest News RSS feed

Bristol Myers Squibb Showcases Positive Results Of New Phase 3 Study Evaluating Cancer Drug Opdivo - Latest News


Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo

The pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) today revealed positive results from a new study evaluating its lead cancer drug Opdivo. The pharma company’s Phase 3 CheckMate-227 trial ... read more

Bristol-Myers Squibb reports positive results from CheckMate -214 phase 3 study of Opdivo in combo with Yervoy to treat advanced/metastatic RCC

Bristol-Myers Squibb Company announced topline results from the CheckMate -214 ... CheckMate -214 is a phase 3, randomized, open-label study evaluating the combination of Opdivo plus Yervoy versus ... read more

Unique combination of Opdivo + Yervoy shows encouraging action in Phase 1/2 bladder cancer study

Follow-up data from a Phase 1/2 clinical trial, CheckMate-032, evaluating Bristol-Myers Squibb's (NYSE:BMY) Opdivo ... No new safety signals were observed. The data support the ongoing Phase 3 ... read more

Looking for another news?


Wired News - Bristol-Myers Squibb's Phase-3 CheckMate-227 Study Met its Co-Primary Endpoint

On February 05, 2018, the Company declared that the ongoing Phase-3 CheckMate-227 study assessing the combination of Opdivo (nivolumab ... a Breakthrough in Cancer Research Giovanni Caforio, M.D., ... read more


Nektar/Bristol-Myers' Combo Trial Positive in Phase I/II

Nektar Therapeutics NKTR along with partner Bristol-Myers Squibb BMY announced positive interim data from dose-escalation part of a phase I/II study, evaluating the ... could provide new treatment ... read more

Bristol-Myers Squibb announces positive results from phase 3 CheckMate -214 trial of Opdivo plus low-dose Yervoy in patients with advanced RCC

Bristol-Myers Squibb Company announced patient-reported ... Annual Meeting 2018 in Chicago CheckMate -214 is a Phase 3, randomised, open-label study evaluating the combination of Opdivo plus Yervoy ... read more

Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results

NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the fourth quarter and full year of 2018 which were highlighted by strong demand for Opdivo (nivolumab ... ... read more

Bristol-Myers Squibb Reports Third Quarter Financial Results

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE ... In September, the company announced results from two Phase 3 clinical trials at the 2015 European Cancer Congress: CheckMate -025 – ... read more

You Should Not Miss Bristol-Myers Squibb In 2018

The drug has been witnessing some exceptional demand in new indications such as first-line renal cancer ... involving Opdivo. Bristol-Myers Squibb expects overall survival or OS data from the PD-L1 ... read more

Bristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration

PRINCETON, N.J., Dec 22, 2014 (BUSINESS WIRE) -- Bristol-Myers Squibb Company BMY, +0.39% today announced that the U.S. Food and Drug ... of cancer immunology. About the CheckMate -037 Trial CheckMate ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us